Ipca Laboratories Ltd
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
- Market Cap ₹ 18,418 Cr.
- Current Price ₹ 726
- High / Low ₹ 1,034 / 670
- Stock P/E 39.1
- Book Value ₹ 230
- Dividend Yield 0.56 %
- ROCE 11.6 %
- ROE 8.32 %
- Face Value ₹ 1.00
Pros
Cons
- Dividend payout has been low at 6.79% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2,359 | 2,813 | 3,282 | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,244 | |
1,894 | 2,248 | 2,539 | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,318 | |
Operating Profit | 465 | 565 | 743 | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 927 |
OPM % | 20% | 20% | 23% | 17% | 10% | 14% | 14% | 19% | 20% | 29% | 23% | 15% |
11 | 13 | 21 | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 126 | |
Interest | 44 | 36 | 30 | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 46 |
Depreciation | 67 | 87 | 103 | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 |
Profit before tax | 364 | 454 | 631 | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 |
Tax % | 24% | 29% | 24% | 28% | 18% | 26% | 18% | 19% | 18% | 17% | 20% | 34% |
Net Profit | 277 | 324 | 479 | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 |
EPS in Rs | 11.01 | 12.82 | 18.96 | 10.07 | 3.69 | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 |
Dividend Payout % | 15% | 16% | 13% | 5% | 0% | 6% | 5% | 9% | 10% | 9% | 11% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 14% |
3 Years: | 11% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | 15% |
3 Years: | -7% |
TTM: | -47% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 17% |
3 Years: | -2% |
1 Year: | -17% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 17% |
3 Years: | 17% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | |
Reserves | 1,229 | 1,529 | 1,934 | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,590 | 4,676 | 5,467 | 5,817 |
601 | 617 | 603 | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | |
472 | 526 | 648 | 669 | 765 | 788 | 799 | 961 | 1,142 | 1,099 | 1,338 | 1,303 | |
Total Liabilities | 2,327 | 2,697 | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,626 |
944 | 1,104 | 1,354 | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,418 | 2,770 | |
CWIP | 95 | 129 | 165 | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 122 |
Investments | 34 | 9 | 9 | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 |
1,255 | 1,455 | 1,683 | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,109 | |
Total Assets | 2,327 | 2,697 | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,626 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
354 | 389 | 522 | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | |
-280 | -260 | -369 | -689 | -218 | -149 | -135 | -165 | -509 | -521 | -851 | -725 | |
-72 | -83 | -136 | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | |
Net Cash Flow | 2 | 46 | 18 | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 432 | 588 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 54 | 54 | 50 | 41 | 57 | 58 | 67 | 66 | 71 | 55 | 57 | 58 |
Inventory Days | 268 | 247 | 272 | 293 | 289 | 290 | 286 | 316 | 294 | 337 | 337 | 276 |
Days Payable | 95 | 89 | 110 | 97 | 145 | 130 | 137 | 154 | 135 | 140 | 101 | 83 |
Cash Conversion Cycle | 227 | 212 | 213 | 237 | 200 | 218 | 216 | 228 | 229 | 251 | 293 | 251 |
Working Capital Days | 117 | 112 | 98 | 106 | 84 | 94 | 107 | 109 | 113 | 119 | 127 | 137 |
ROCE % | 24% | 24% | 28% | 14% | 5% | 9% | 10% | 16% | 19% | 31% | 20% | 12% |
Documents
Announcements
-
Income Tax Survey
1d - The Income Tax Department has carried out survey proceedings at the Company's offices in Mumbai and at Sikkim manufacturing plants between 30th May, 2023 to …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jun - Copies of the Newspaper publication of Audited Financial Results for the 4th quarter and financial year ended 31st March, 2023 published on 30th May, 2023 …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
30 May - The Q4FY23 results conference call of Ipca Laboratories Ltd. has been cancelled due to unavoidable circumstances. The new date for the call will be communicated …
- Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2023. 29 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Copy of the Annual Secretarial Compliance Report for the period ended March 31, 2023
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Apr 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]
Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]